Helge B.
- Country
- Germany
- Department
- Thoraxklinik
Research Overview
- A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
- Phase 3 Randomized Placebo‑Controlled Trial of Adjuvant mRNA‑4157 (Intismeran) Plus Pembrolizumab Combination Therapy in Completely Resected High‑Risk Stage I NSCLC
- Phase 3 Randomized Open‑Label Trial of ABBV‑706 versus Standard of Care in Relapsed/Refractory Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 267 of 508 partner sites.
Specializations
Advanced Lung Cancer
This investigator specializes in treating various forms of non-small cell lung cancer (NSCLC), with particular focus on advanced and metastatic disease states. Their research encompasses both squamous and non-squamous NSCLC variants.
- Metastatic NSCLC Management
- Advanced Stage Treatment Protocols
- Resectable Lung Cancer
Genetic and Molecular Oncology
The investigator focuses on targeted therapies for specific genetic mutations in lung cancer, including EGFR mutations, ALK-positive cases, and RET fusion-positive NSCLC.
- Molecular Targeting Therapies
- Genetic Mutation Analysis
- Biomarker-Driven Treatment
Immunotherapy Research
Their work includes extensive research in immunotherapy approaches for lung cancer treatment, particularly focusing on PD-L1 expression and novel combination therapies.
- Combination Immunotherapy
- Treatment-Resistant Cases
- Novel Therapeutic Approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.